Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

@article{Marshall2004PhaseIT,
  title={Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor},
  author={John Marshall and Hedy Lee Kindler and John F Deeken and Pankaj Bhargava and Nicholas John Vogelzang and Naiyer A Rizvi and Taina Luhtala and Stacy Boylan and Margaret Dordal and Philmore Robertson and Michael J. Hawkins and Mark J. Ratain},
  journal={Investigational New Drugs},
  year={2004},
  volume={23},
  pages={31-37}
}
Purpose: A phase I clinical trial in patients with advanced carcinomas was conducted using the orally available neurotrophin receptor-linked tyrosine kinase receptor inhibitor, CEP-701. The objectives were to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic profile of this orally administered agent. Patients and methods: A total of 30 patients were accrued to receive escalating BID doses of CEP-701 in cycles lasting 28 days. Between 3 and 6 patients were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

TrkB as a therapeutic target for ovarian cancer.

Expert opinion on therapeutic targets • 2009
View 8 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Clinical cancer research : an official journal of the American Association for Cancer Research • 1998
View 6 Excerpts
Highly Influenced

Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1999
View 2 Excerpts

cancer

MM Berg, DW Stenberg, LF Parada, MV Chao
1998

Similar Papers

Loading similar papers…